Encouraging Phase 3 Results: Marstacimab for Hemophilia A or B with Inhibitors
Heme Today shared a thrilled post on LinkedIn:
”ICYMI in hemophilia reporting on Heme Today: Marstacimab from Pfizer performed impressively in a phase 3 study as tx for hemophilia A or B with inhibitors.”
To learn more, follow the link.
A phase 3 study has yielded favorable topline results for Marstacimab (HYMPAVZI), showing promising efficacy and safety in treating severe hemophilia A or B with inhibitors.
Pfizer announced the positive findings, highlighting the therapy’s potential to address an important unmet need for patients with antibodies that limit factor-based prophylaxis.
“These encouraging results demonstrate HYMPAVZI’s potential to help people living with hemophilia A or B with inhibitors, meeting an important need for patients with antibodies that neutralize most factor-based prophylactic options used to manage bleeding episodes,” commented Pfizer’s chief inflammation & immunology officer Michael Vincent, MD, PhD.
Stay updated on the latest scientific advancements in the field of hemophilia management with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis